{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-23-000111","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2023-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.991192+00:00","generated_at":"2026-06-09T05:10:40.642022+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Pfizer Q3 revenue $13.2B (-42% YoY), adjusted LPS $(0.17) on $5.6B write-off; reaffirms FY guidance","bullets":["Q3 revenues $13.2B, down 41% operationally; non-COVID products grew 10% operationally.","Reported diluted LPS $(0.42); adjusted diluted LPS $(0.17), including $5.6B non-cash inventory write-offs.","Reaffirms FY2023 guidance: revenue $58-61B, adjusted EPS $1.45-$1.65; expects $1B cost savings in 2023.","Comirnaty revenue down 70% operationally; Paxlovid down 97% operationally; Abrysvo contributed $375M.","Launched enterprise cost realignment program targeting at least $3.5B annual net savings by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-23-000111","json":"https://secwatch.observer/filing/0000078003-23-000111.json","markdown":"https://secwatch.observer/filing/0000078003-23-000111.md","text":"https://secwatch.observer/filing/0000078003-23-000111.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000111/0000078003-23-000111-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000111/pfe-20231031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T05:10:40.642022+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"53c897b11464d4a080ad2682e43f503e1f022a36","claim":"PFIZER INC reported the third quarter of 2023 results: revenue Revenues of $13.2 Billion, net income Reported (2) Net Income/(Loss) (2,382), EPS Reported (2) Diluted EPS/(LPS) (0.42). Guidance reaffirmed.","evidence_excerpt":"except as shall be expressly set forth by specific reference in such filing. --- EX-99 (EX-99) --- Pfizer Reports Third-Quarter 2023 Results ▪ Third-Quarter 2023 Revenues of $13.2 Billion – Expected Decline in Paxlovid and Comirnaty (1) Revenues Drove 41% Operational Decrease in Third-Quarter 2023 Revenues – Revenues for Pfizer’s Non-COVID Products Grew 10%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000111/0000078003-23-000111-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2023"},{"label":"Revenue","value":"Revenues of $13.2 Billion"},{"label":"Net income","value":"Reported (2) Net Income/(Loss) (2,382)"},{"label":"EPS","value":"Reported (2) Diluted EPS/(LPS) (0.42)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}